CNSY.US Cerenome, Inc.
- Market cap
- USD 7.21M
- P/E
- -
- P/B
- 1.31x
- ROE
- -584.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CNSY.US undervalued?
Graham numberThe Graham number of Cerenome, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cerenome, Inc. fundamental analysis
No fundamental analysis for Cerenome, Inc. yet.
Cerenome, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere…
Full company profileCerenome, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cerenome, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.4M | 6.41M | 2.98M | 7.00M | 303K | - | 224K | 4.91M | 5.82M | 5.21M | 2.88M |
| Gross Profit | 8.67M | 5.09M | 1.84M | 7.00M | -2.40M | -66.0K | -488K | -4.78M | 4.97M | 4.77M | 2.36M |
| Operating Income | -19.7M | -20.7M | -8.76M | -3.66M | -9.58M | -12.5M | -19.7M | -13.3M | -14.7M | -15.3M | -32.4M |
| EBITDA | -18.3M | -18.5M | -6.58M | -532K | -8.44M | -12.1M | -18.9M | -12.3M | -8.38M | -18.3M | -31.5M |
| Net Income | -22.0M | -22.7M | -12.6M | -10.9M | -8.24M | -13.4M | -20.3M | -13.3M | -13.0M | -22.4M | -31.9M |
| EPS | -31,858 | -1,334,471 | -27,465,217 | -2,950,407 | -686,750 | -418,719 | -289,643 | -105,683 | -42 | -7.19 | -4.71 |
| Balance Sheet | |||||||||||
| Total Assets | 34.6M | 31.6M | 24.0M | 23.2M | 12.1M | 22.0M | 23.9M | 11.4M | 6.63M | 16.3M | 14.0M |
| Total Liabilities | 23.6M | 18.6M | 18.8M | 22.1M | 9.07M | 11.1M | 17.4M | 12.7M | 15.6M | 12.3M | 8.57M |
| Shareholders' Equity | 11.0M | 13.0M | 5.23M | 1.16M | 3.03M | 10.8M | 6.45M | -1.35M | -8.95M | 4.00M | 5.46M |
| Cash & Short-term Investments | 12.6M | 9.55M | 5.26M | 17.6M | 8.35M | 18.4M | 18.1M | 8.55M | 3.61M | 8.76M | 8.59M |
| Total Debt | 17.6M | 13.6M | 14.2M | 12.0M | 7.00M | 6.99M | 5.76M | 4.18M | 3.37M | 821K | 44.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.5M | -18.1M | -12.0M | -5.91M | -8.43M | -10.3M | -13.0M | -12.9M | -10.6M | -20.8M | -26.7M |
| Capital Expenditure | 67.0K | 1.50M | 133K | 67.0K | 493K | 144K | 759K | 160K | 146K | 67.0K | 2.63M |
| Free Cash Flow | -19.6M | -19.6M | -12.1M | -5.97M | -8.93M | -10.4M | -13.7M | -13.0M | -10.7M | -20.8M | -29.4M |
| Ratios | |||||||||||
| ROE | -200.7% | -174.5% | -241.8% | -938.5% | -271.9% | -123.7% | -314.6% | - | - | -560.2% | -584.0% |
| ROA | -63.7% | -71.8% | -52.7% | -46.9% | -68.1% | -61.0% | -84.9% | -116.9% | -195.7% | -137.1% | -227.4% |
| Net Profit Margin | -193.7% | -353.9% | -423.5% | -155.6% | -2,719.8% | - | -9,051.3% | -271.0% | -222.8% | -429.4% | -1,108.5% |
| Debt to Equity | 1.61x | 1.05x | 2.72x | 10.32x | 2.31x | 0.65x | 0.89x | - | - | 0.21x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cerenome, Inc. dividends
Cerenome, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Apr 2, 2026.
Who owns Cerenome, Inc.
- Insiders 2.02%
- Institutions 15.71%
- Public & others 82.27%
- Shares outstanding 7.59M
- Free float 7.50M
Top funds holding CNSY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 219K | 2.88% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 41.0K | 0.54% | -0.37% | Sep 2026 |
| iShares Micro-Cap ETF | 25.7K | 0.34% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 12.9K | 0.17% | 0.00% | Sep 2026 |
| Abante Quant Value FI | 10.8K | 0.14% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 10.1K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.85K | 0.04% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.28K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 1.52K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding CNSY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 305K | 4.02% | 0.00% | Jun 2026 |
| BlackRock Inc | 96.0K | 1.26% | +35.08% | Jun 2026 |
| Geode Capital Management, LLC | 76.2K | 1.00% | -5.58% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 36.9K | 0.49% | 0.00% | Jun 2026 |
| State Street Corp | 30.9K | 0.41% | +64.50% | Jun 2026 |
| Citadel Advisors Llc | 25.6K | 0.34% | 0.00% | Jun 2026 |
| Northern Trust Corp | 15.5K | 0.20% | +32.25% | Jun 2026 |
| Virtu Financial LLC | 15.3K | 0.20% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 11.6K | 0.15% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 6.16K | 0.08% | +307,700.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 2.28K | 0.03% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.00K | 0.03% | +39,900.00% | Jun 2026 |
| Tower Research Capital LLC | 1.96K | 0.03% | 0.00% | Jun 2026 |
| Allied Private Wealth LLC | 496.00 | 0.01% | 0.00% | Jun 2026 |
| UBS Group AG | 470.00 | 0.01% | -86.62% | Jun 2026 |
| SBI Securities Co Ltd | 251.00 | 0.00% | +136.79% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 185.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 96.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 64.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 17.00 | 0.00% | -99.54% | Jun 2026 |
Cerenome, Inc. company profile
- Company name
- Cerenome, Inc.
- Ticker
- CNSY.US
- Exchange
- USA Stocks
- Listed since
- Nov 16, 2000
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Fiscal year end
- December
- Address
- 6420 Levit Green Blvd, Houston, TX, United States, 77021
- Phone
- 210 974 6900
- Website
- cerenome.com
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Cerenome, Inc. management
2- Dr. Marc H. Hedrick M.B.A., M.D.President, CEO & Director · born 1963
- Mr. Andrew J. Sims CPAVP & CFO · born 1973